Literature DB >> 24883238

Genetics of Psychosis in Alzheimer Disease.

Mary Ann A DeMichele-Sweet1, Robert A Sweet2.   

Abstract

Psychosis occurs in approximately half of patients with Alzheimer disease (AD with psychosis, AD+P). AD+P patients have more rapid cognitive decline, greater behavioral symptoms, and higher mortality than do AD patients without psychosis. Studies in three independent cohorts have shown that psychosis in AD aggregates in families, with estimated heritability of 29.5 - 60.8%. These findings have motivated studies to investigate and uncover the genes responsible for the development of psychosis, with the ultimate goal of identifying potential biologic mechanisms that may serve as leads to specific therapies. Linkage analyses have implicated loci on chromosomes 2, 6, 7, 8, 15, and 21 with AD+P. Association studies of APOE do not support it as a risk gene for psychosis in AD. No other candidate genes, such as neurodegenerative and monoamine genes, show conclusive evidence of association with AD+P. However, a recent genome-side association study has produced some promising leads, including among them genes that have been associated with schizophrenia. This review summarizes the current knowledge of the genetic basis of AD+P.

Entities:  

Keywords:  Alzheimer disease; Association Study; Genome-wide association; Heritability; Linkage Analysis; Psychosis

Year:  2014        PMID: 24883238      PMCID: PMC4034371          DOI: 10.1007/s40142-014-0030-1

Source DB:  PubMed          Journal:  Curr Genet Med Rep        ISSN: 2167-4876


  75 in total

Review 1.  Serotonin in Alzheimer-type dementia and other dementing illnesses.

Authors:  A J Cross
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

Authors:  A V Cheng; I N Ferrier; C M Morris; S Jabeen; A Sahgal; I G McKeith; J A Edwardson; R H Perry; E K Perry
Journal:  J Neurol Sci       Date:  1991-11       Impact factor: 3.181

4.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

5.  A highly significant association between a COMT haplotype and schizophrenia.

Authors:  Sagiv Shifman; Michal Bronstein; Meira Sternfeld; Anne Pisanté-Shalom; Efrat Lev-Lehman; Avraham Weizman; Ilya Reznik; Baruch Spivak; Nimrod Grisaru; Leon Karp; Richard Schiffer; Moshe Kotler; Rael D Strous; Marnina Swartz-Vanetik; Haim Y Knobler; Eilat Shinar; Jacques S Beckmann; Benjamin Yakir; Neil Risch; Naomi B Zak; Ariel Darvasi
Journal:  Am J Hum Genet       Date:  2002-10-25       Impact factor: 11.025

6.  Psychotic symptoms and physically aggressive behavior in Alzheimer's disease.

Authors:  D W Gilley; R S Wilson; L A Beckett; D A Evans
Journal:  J Am Geriatr Soc       Date:  1997-09       Impact factor: 5.562

7.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

Review 8.  Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies.

Authors:  Stephen W Scheff; Douglas A Price
Journal:  Neurobiol Aging       Date:  2003-12       Impact factor: 4.673

9.  Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e.

Authors:  Mary Ann A Demichele-Sweet; Oscar L Lopez; Robert A Sweet
Journal:  Int J Alzheimers Dis       Date:  2011-03-23

10.  Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1.

Authors:  Francis J McMahon; Nirmala Akula; Thomas G Schulze; Pierandrea Muglia; Federica Tozzi; Sevilla D Detera-Wadleigh; C J M Steele; René Breuer; Jana Strohmaier; Jens R Wendland; Manuel Mattheisen; Thomas W Mühleisen; Wolfgang Maier; Markus M Nöthen; Sven Cichon; Anne Farmer; John B Vincent; Florian Holsboer; Martin Preisig; Marcella Rietschel
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

View more
  5 in total

1.  Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease.

Authors:  Winnie Qian; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

2.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  A Bayesian model of psychosis symptom trajectory in Alzheimer's disease.

Authors:  Howard J Seltman; Shaina Mitchell; Robert A Sweet
Journal:  Int J Geriatr Psychiatry       Date:  2015-07-27       Impact factor: 3.485

Review 4.  Focus on psychosis.

Authors:  Wolfgang Gaebel; Jürgen Zielasek
Journal:  Dialogues Clin Neurosci       Date:  2015-03       Impact factor: 5.986

5.  Mediation of insulin growth factor-1 in Alzheimer's disease and the mechanism of PRNP genetic expression and the PI3K/Akt signaling pathway.

Authors:  Guohong Jiang; Changming Wang; Jun Zhang; Haijun Liu
Journal:  Exp Ther Med       Date:  2017-04-10       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.